Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

DGAP-Adhoc: Carl Zeiss Meditec AG expects revenue for fiscal year 2019/20 of approx. EUR 1.3 billion

eqs_en 
0 0 15.07.20
DGAP-Adhoc: Carl Zeiss Meditec AG expects revenue for fiscal year 2019/20 of approx. EUR 1.3 billion http://www.meditec.zeiss.com/C125679E0051C774?Open: CARL ZEISS MEDITEC AG
 

DGAP-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): 9 Month figures/Forecast
Carl Zeiss Meditec AG expects revenue for fiscal year 2019/20 of approx. EUR 1.3 billion

15-Jul-2020 / 09:35 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Carl Zeiss Meditec AG expects revenue for fiscal year 2019/20 of approx. EUR 1.3 billion
Jena, July 15, 2020

In view of the continuing Covid-19 pandemic and its impact on relevant markets, Carl Zeiss Meditec AG (ISIN: DE0005313704) expects to see a further impact on business development in the remainder of fiscal year 2019/20 compared to previous year.

Assuming a recovery in markets and, in particular, that no significant additional measures to contain the Covid-19 pandemic will impact development, management anticipates revenue of around EUR 1.3 billion for fiscal year 2019/20 (previous year EUR 1.459 billion).

In the first nine months of fiscal year 2019/20, Carl Zeiss Meditec has achieved revenue of EUR 967.9 million (previous year EUR 1,027.6 million). This corresponds to a decline of 5.8% vs. the previous year. After adjustment for currency effects[1], the decline amounted to 6.9%.

Earnings before interest and taxes (EBIT) amounted to EUR 111.9 million after the first nine months of 2019/20 (previous year: EUR 184.2 million). Earnings per share (EPS) were EUR 0.77 (previous year: EUR 1.22).

The quarterly statement of the first nine months of fiscal year 2019/20 will be published on August 5, 2020.
 
 

Contact for investors and press
Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Tel.: +49 3641 220-116
E-Mail: [email protected]

[1] Currency-adjusted revenue growth is calculated by converting current period revenue with the exchange rates of the previous year's period.

15-Jul-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: Carl Zeiss Meditec AG
Göschwitzer Str. 51-52
07745 Jena, Germany
Germany
Phone: +49 (0)3641 220-0
Fax: +49 (0)3641 220-112
E-mail: [email protected]
Internet: www.zeiss.de/meditec-ag/ir
ISIN: DE0005313704
WKN: 531370
Indices: MDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1093951

 
End of Announcement DGAP News Service

1093951  15-Jul-2020 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1093951&application_name=news&site_id=sharewise

Carl Zeiss Meditec AG Stock

€102.00
-1.350%
A loss of -1.350% shows a downward development for Carl Zeiss Meditec AG.
Our community is currently high on Carl Zeiss Meditec AG with 3 Buy predictions and 1 Sell predictions.
As a result the target price of 109 € shows a slightly positive potential of 6.86% compared to the current price of 102.0 € for Carl Zeiss Meditec AG.
Show more
Like: 0
Share
eqs_en 
EQS Group is a leading international provider of regulatory technology in the fields of corporate compliance and investor relations. In working with EQS Group, thousands of companies worldwide inspire trust by fulfilling complex national and international disclosure obligations, minimizing risks and communicating transparently with stakeholders.




Legal notice

Comments

Not a member yet? Sign up for free!